each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkylene-NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and $-C_{1-4}$ alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and $-NR^{12}R^{13}$;

each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl;

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkylene-NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and $-C_{1-4}$ alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group $-(C(R^a)_2)_p-$ linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, oxo, $-C_{1-4}$ alkylene-NR^7R^8, $-C_{1-4}$ alkylene-NHOH, $-C_{1-4}$ alkylene-NR^9COR^{10}, $-C_{1-4}$ alkylene-$NR^9SO_2R^{10}$, $-C_{1-4}$ alkylene-NR^9COOR^{10}, $-C_{1-4}$ alkylene-$NR^9CONR^7R^8$, $-C_{1-4}$ alkylene-$NR^9SO_2NR^7R^8$, $-C_{1-4}$ alkylene-OH and $-C_{1-4}$ alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S,

B is hydrogen, R^1 or –L-E;

E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^2;

L is a bond, -O-, -NH-, -N(C_{1-4} alkyl)-, C_{1-4} alkylene or heteroC_{1-4} alkylene;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group -$(C(R^a)_2)_p$- linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or


(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from –NR^7R^8, -NHOH, -NR^9COR^{10}, -$NR^9SO_2R^{10}$, -NR^9COOR^{10}, -$NR^9CONR^7R^8$, -$NR^9SO_2NR^7R^8$, -OH, –$CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkylene-NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and –C_{1-4} alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;



Ia

wherein:

A is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^1;

B is hydrogen, R^1 or –L-E;

E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^2;

L is a bond, -O-, -NH-, -N(C_{1-4} alkyl)-, C_{1-4} alkylene or heteroC_{1-4} alkylene;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group -$(C(R^a)_2)_p$- linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from –NR^7R^8, -NHOH, -NR^9COR^{10}, -$NR^9SO_2R^{10}$, -NR^9COOR^{10}, -$NR^9CONR^7R^8$, -$NR^9SO_2NR^7R^8$, -OH, –$CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkylene-

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkylene-NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and $-C_{1-4}$ alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and $-NR^{12}R^{13}$;

each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl;

each R^{14} is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea; and

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkylene-NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and $-C_{1-4}$ alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and $-NR^{12}R^{13}$;


each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl; and

17. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one substituent R^3 and is further optionally substituted with one or more R^4.

18. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one substituent R^3.

19. The compound of any of claims 1 to 3 or 16 to 18 or the compound for use as a medicament according to any of claims 4 to 6 or 16 to 18 or the pharmaceutical composition of any of claims 7 to 9 or 16 to 18, wherein the cycloalkyl group having from 4 to 7 C atoms which forms part of D is a cyclohexyl group.


20. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is



,

wherein the cyclobutyl ring comprised in D is optionally substituted with one or more R^4.

21. The compound of any of claims 1 to 3 or the compound for use as a medicament according to any of claims 4 to 6 or the pharmaceutical composition of any of claims 7 to 9, wherein D is



,

wherein the cyclohexyl ring comprised in D is optionally substituted with one or more R^4.

22. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, $-CONR^7R^8$, oxo, $-C_{1-4}$ alkylene-NR^7R^8, $-C_{1-4}$ alkylene-NHOH, $-C_{1-4}$ alkylene-NR^9COR^{10}, $-C_{1-4}$ alkylene-$NR^9SO_2R^{10}$, $-C_{1-4}$ alkylene-NR^9COOR^{10}, $-C_{1-4}$ alkylene-$NR^9CONR^7R^8$, $-C_{1-4}$ alkylene-$NR^9SO_2NR^7R^8$, $-C_{1-4}$ alkylene-OH and $-C_{1-4}$ alkylene-$CONR^7R^8$.

23. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, oxo, $-C_{1-4}$ alkylene-NR^7R^8, $-C_{1-4}$ alkylene-NHOH, $-C_{1-4}$ alkylene-NR^9COR^{10}, $-C_{1-4}$ alkylene-$NR^9SO_2R^{10}$, $-C_{1-4}$ alkylene-NR^9COOR^{10}, $-C_{1-4}$ alkylene-$NR^9CONR^7R^8$, $-C_{1-4}$ alkylene-$NR^9SO_2NR^7R^8$, and $-C_{1-4}$ alkylene-OH.

24. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, and oxo.

25. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, -OH, $-CONR^7R^8$, and oxo.

26. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$, -OH, oxo, $-C_{1-4}$ alkylene-NR^7R^8, and $-C_{1-4}$ alkylene-OH.

27. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$ and $-C_{1-4}$ alkylene-NR^7R^8.

28. The compound of any of claims 1 to 3 or 10 to 21 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 21 or the pharmaceutical composition of any of claims 7 to 21, wherein each R^3 is independently selected from $-NR^7R^8$.

29. The compound of any of claims 1 to 3 or 10 to 28 or the compound for use as a medicament according to any of claims 4 to 6 or 10 to 28 or the pharmaceutical composition of any of claims 7 to 28, wherein R^7 and R^8 are each independently selected from hydrogen, C_{1-8} alkyl, H_2N-C_{1-8} alkyl and hydroxyC_{1-8} alkyl.

90. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N1-((*trans*)-2-phenylcyclopropyl)cyclobutane-1,3-diamine, an optically active stereoisomer thereof, or a salt or solvate thereof.

91. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N1-((trans)-2-(pyridin-3-yl)cyclopropyl)cyclohexane-1,4-diamine, an optically active stereoisomer thereof, or a salt or solvate thereof.

92. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N1-methyl-N4-((*trans*)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, an optically active stereoisomer thereof, or a salt or solvate thereof.

93. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N1-((*trans*)-2-(4-(1H-pyrazol-5-yl)phenyl)cyclopropyl)cyclohexane-1,4-diamine, an optically active stereoisomer thereof, or a salt or solvate thereof.

94. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N-(4'-((*trans*)-2-((4-aminocyclohexyl)amino)cyclopropyl)-[1,1'-biphenyl]-3-yl)piperazine-1-sulfonamide, an optically active stereoisomer thereof, or a salt or solvate thereof.

95. The compound of claim 1, the compound for use as a medicament according to claim 4 or the pharmaceutical composition of claim 7, wherein said compound is N1-((*trans*)-2-(4-((2-fluorobenzyl)oxy)phenyl)cyclopropyl)cyclohexane-1,4-diamine, an optically active stereoisomer thereof, or a salt or solvate thereof.

96. The compound of any of claims 1, 2, 10 to 81, 86 or 89 to 95 or the compound for use as a medicament according to any of claims 4 to 6, 10 to 81, 86 or 89 to 95 or the pharmaceutical composition of any of claims 7 to 81, 86 or 89 to 95, wherein said compound is an optically active stereoisomer.

97. Use of ~~The compound of any of claims 1 to 3 or 10 to 96 or~~ a compound as defined in any of claims 4 1 to ~~6~~ 5 or 10 to 96 ~~or the pharmaceutical composition of any of claims 7 to 96 for use in~~ for the preparation of a medicament for the treatment or prevention of cancer.

98. The ~~compound for~~ use according to claim 97 ~~or the pharmaceutical composition for use according to claim 97~~, wherein said cancer is chosen from breast cancer, lung cancer, prostate cancer, colorectal cancer, brain cancer, skin cancer, blood cancer, leukemia, lymphoma and myeloma.

99. The ~~compound for~~ use according to claim 97 ~~or the pharmaceutical composition for use according to claim 97~~, wherein said cancer is blood cancer.

100. The ~~compound for~~ use according to claim 97 ~~or the pharmaceutical composition for use according to claim 97~~, wherein said cancer is leukemia.

101. The ~~compound for~~ use according to claim 98 or 100 ~~or the pharmaceutical composition for use according to claim 98 or 100~~, wherein said leukemia is chosen from acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia, chronic eosinophilic leukemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and hairy cell leukemia.

102. Use of ~~The compound of any of claims 1 to 3 or 10 to 96 or~~ a compound as defined in any of claims 4 1 to ~~6~~ 5 or 10 to 96 ~~or the pharmaceutical composition of any of claims 7 to 96 for use in~~ for the preparation of a medicament for the treatment or prevention of a neurological disease.

103. The ~~compound for~~ use according to claim 102 ~~or the pharmaceutical composition for use according to claim 102~~, wherein said neurological disease is selected from depression, Alzheimer's disease, Huntington disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, Dementia with Lewy Bodies, or Frontotemporal Dementia.

104. Use of ~~The compound of any of claims 1 to 3 or 10 to 96 or~~ a compound as defined in any of claims 4 1 to ~~6~~ 5 or 10 to 96 ~~or the pharmaceutical composition of any of claims 7 to 96 for use in~~ for the preparation of a medicament for the treatment or prevention a viral infection.

105. The ~~compound for~~ use according to claim 104 ~~or the pharmaceutical composition for use according to claim 104~~, wherein said viral infection is a herpesvirus infection.

106. The ~~compound for~~ use according to claim 105 ~~or the pharmaceutical composition for use according to claim 105~~, wherein said herpesvirus infection is caused by and/or associated with a herpesvirus chosen from HSV-1, HSV-2 and Epstein-Barr virus.

107. The ~~compound for~~ use according to claim 104 ~~or the pharmaceutical composition for use according to claim 104~~, wherein said viral infection is caused by and/or associated with HIV.

108. The ~~compound for~~ use according to claim 104 ~~or the pharmaceutical composition for use according to claim 104~~, wherein said viral infection is caused by and/or associated with a *Hepadnavirus.*

109. The ~~compound for~~ use according to claim 108 ~~or the pharmaceutical composition for use according to claim 108~~, wherein said *Hepadnavirus* is Hepatitis B virus.

110. The ~~compound for~~ use according to claim 104 ~~or the pharmaceutical composition for use according to claim 104~~, wherein said viral infection is caused by and/or associated with a *Flavivirus.*

111. The ~~compound for~~ use according to claim 110 ~~or the pharmaceutical composition for use according to claim 110~~, wherein said *Flavivirus* is chosen from Hepatitis C virus (HCV), yellow fever virus, West Nile virus, Dengue virus and Japanese encephalitis virus.


112. Use of ~~The compound of any of claims 1 to 3 or 10 to 96 or~~ a compound as defined in any of claims 4 1 to ~~6~~ 5 or 10 to 96 ~~or the pharmaceutical composition of any of claims 7 to 96 for use in~~ for the preparation of a medicament for the treatment or prevention of viral reactivation after latency.

113. The ~~compound for~~ use according to claim 112 ~~or the pharmaceutical composition for use according to claim 112~~, wherein the virus that is reactivating is a herpesvirus.

114. The ~~compound for~~ use according to claim 113 ~~or the pharmaceutical composition for use according to claim 113~~, wherein said herpesvirus is chosen from HSV-1, HSV-2 and Epstein-Barr virus.

115. The ~~compound for~~ use according to claim 112 ~~or the pharmaceutical composition for use according to claim 112~~, wherein the virus that is reactivating is HIV.

116. Use of ~~A method of treating or preventing cancer, the method comprising administering, to a subject in need of such treatment or prevention,~~ a compound of formula I



I

wherein:

A is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^1;

B is hydrogen, R^1 or –L-E;

E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^2;

L is a bond, -O-, -NH-, -N(C_{1-4} alkyl)-, C_{1-4} alkylene or heteroC_{1-4} alkylene;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group -$\{C(R^a)_2\}_p$- linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from –NR^7R^8, -NHOH, -NR^9COR^{10}, -$NR^9SO_2R^{10}$, -NR^9COOR^{10}, -$NR^9CONR^7R^8$, -$NR^9SO_2NR^7R^8$, -OH, –$CONR^7R^8$, oxo, -C_{1-4} alkylene-NR^7R^8, -C_{1-4} alkylene-NHOH, -C_{1-4} alkylene-NR^9COR^{10}, -C_{1-4} alkylene-$NR^9SO_2R^{10}$, -C_{1-4} alkylene-NR^9COOR^{10}, -C_{1-4} alkylene-$NR^9CONR^7R^8$, -C_{1-4} alkylene-$NR^9SO_2NR^7R^8$, -C_{1-4} alkylene-OH and –C_{1-4} alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and $-NR^{12}R^{13}$;


each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl;

each R^{14} is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea; and

each R^w, R^x, R^y and R^z is independently selected from hydrogen, halo and C_{1-4} alkyl;
or a salt or solvate thereof;
with the proviso that the following compounds are excluded:
2-((2-phenylcyclopropyl)amino)cycloheptanol, and
2-((2-phenylcyclopropyl)amino)cyclopentanol;

for the preparation of a medicament for treating or preventing cancer.

~~117. The method of claim 116, wherein said compound is a compound of formula Ia~~



Ia

wherein:

A is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^1;

B is hydrogen, R^1 or -L-E;

E is aryl or heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with one or more R^2;

L is a bond, -O-, -NH-, -N(C_{1-4} alkyl)-, C_{1-4} alkylene or heteroC_{1-4} alkylene;

D is a cycloalkyl group having from 4 to 7 C atoms, wherein said cycloalkyl group has one or two substituents R^3 and is further optionally substituted with one or more R^4, and wherein the cycloalkyl group optionally:

(a) is fused to a phenyl or a 5- or 6-membered aromatic heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said fused phenyl or said fused aromatic heterocyclic ring is optionally substituted with one or more R^5; or

(b) is bonded to a linker group $-(C(R^a)_2)_p-$ linking together any two non-adjacent ring carbon atoms of the cycloalkyl group, wherein p is 1 or 2 and each R^a independently is hydrogen or C_{1-4} alkyl; or

(c) is linked to a second ring that is either a 3- to 7-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocyclic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, wherein said second ring is linked together with the cycloalkyl group via a single carbon atom common to both rings, and wherein said second ring is optionally substituted with one or more R^6;

each R^1 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^2 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^3 is independently selected from $-NR^7R^8$, -NHOH, $-NR^9COR^{10}$, $-NR^9SO_2R^{10}$, $-NR^9COOR^{10}$, $-NR^9CONR^7R^8$, $-NR^9SO_2NR^7R^8$, -OH, $-CONR^7R^8$, oxo, C_{1-4} alkylene-NR^7R^8, C_{1-4} alkylene-NHOH, C_{1-4} alkyene-

NR^9COR^{10}, $-C_{1-4}$ alkylene-$NR^9SO_2R^{10}$, $-C_{1-4}$ alkylene-NR^9COOR^{10}, $-C_{1-4}$ alkylene-$NR^9CONR^7R^8$, $-C_{1-4}$ alkylene-$NR^9SO_2NR^7R^8$, $-C_{1-4}$ alkylene-OH and $-C_{1-4}$ alkylene-$CONR^7R^8$;

each R^4 and each R^6 is independently selected from C_{1-8} alkyl, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy and C_{1-8} alkoxy;

each R^5 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

each R^7 and each R^8 is independently selected from hydrogen, C_{1-8} alkyl, $R^{12}R^{13}N$-C_{1-8} alkyl and hydroxyC_{1-8} alkyl, or R^7 and R^8 are linked together to form, along with the N atom to which they are bound, a saturated 3- to 7-membered heterocyclic ring which optionally contains one further heteroatom selected from N, O and S, wherein one or more C atoms in said heterocyclic ring are optionally oxidized to form CO groups, wherein one or more S atoms in said heterocyclic ring, if present, are optionally oxidized to form independently SO groups or SO_2 groups, and wherein said heterocyclic ring is optionally substituted with one or more R^{11};

each R^9 is independently selected from hydrogen and C_{1-4} alkyl;

each R^{10} is independently selected from C_{1-8} alkyl, haloC_{1-8} alkyl, cyclyl and cyclylC_{1-8} alkyl, wherein said cyclyl or the cyclyl moiety comprised in said cyclylC_{1-8} alkyl is optionally substituted with one or more R^{14};

each R^{11} is independently selected from C_{1-8} alkyl, halo, C_{1-8} alkoxy, hydroxyl and $-NR^{12}R^{13}$;

each R^{12} and each R^{13} is independently selected from hydrogen and C_{1-8} alkyl; and

each R^{14} is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, amino, amido, hydroxyl, nitro, halo, haloC_{1-8} alkyl, haloC_{1-8} alkoxy, cyano, sulfinyl, sulfonyl, sulfonamide, C_{1-8} alkoxy, acyl, carboxyl, O-carboxy, C-carboxy, carbamate and urea;

or a salt or solvate thereof;

with the proviso that the following compounds are excluded:
2-((2-phenylcyclopropyl)amino)cycloheptanol, and
2-((2-phenylcyclopropyl)amino)cyclopentanol.

118. A method of treating or preventing a disease, the method comprising administering, to a subject in need of such treatment or prevention, the compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96.

119. A method of treating or preventing cancer, the method comprising administering, to a subject in need of such treatment or prevention, the compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96.

120. The method of any of claims 116, 117 or 119, wherein said cancer is chosen from breast cancer, lung cancer, prostate cancer, colorectal cancer, brain cancer, skin cancer, blood cancer, leukemia, lymphoma and myeloma.

121. The method of claim 120, wherein said cancer is blood cancer.

122. The method of claim 120, wherein said cancer is leukemia.

123. The method of claim 120 or 122, wherein said leukemia is chosen from acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia, chronic eosinophilic leukemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and hairy cell leukemia.

124. A method of treating or preventing a neurological disease, the method comprising administering, to a subject in need of such treatment or prevention, the compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96.

125. The method of claim 124, wherein said neurological disease is selected from depression, Alzheimer's disease, Huntington disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, Dementia with Lewy Bodies, or Frontotemporal Dementia.

126. A method of treating or preventing a viral infection, the method comprising administering, to a subject in need of such treatment or prevention, the compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96.

127. The method of claim 126, wherein said viral infection is a herpesvirus infection.

128. The method of claim 127, wherein said herpesvirus infection is caused by and/or associated with a herpesvirus chosen from HSV-1, HSV-2 and Epstein-Barr virus.

~~129. The method of claim 126, wherein said viral infection is caused by and/or associated with HIV.~~

~~130. The method of claim 126, wherein said viral infection is caused by and/or associated with a *Hepadnavirus*.~~

~~131. The method of claim 130, wherein said *Hepadnavirus* is Hepatitis B virus.~~

~~132. The method of claim 126, wherein said viral infection is caused by and/or associated with a *Flavivirus*.~~

~~133. The method of claim 132, wherein said *Flavivirus* is chosen from Hepatitis C virus (HCV), yellow fever virus, West Nile virus, Dengue virus and Japanese encephalitis virus.~~

~~134. A method for treating or preventing viral reactivation after latency, the method comprising administering, to a subject in need of such treatment or prevention, the compound of any of claims 1 to 3 or 10 to 96 or a compound as defined in any of claims 4 to 6 or 10 to 96 or the pharmaceutical composition of any of claims 7 to 96.~~


~~135. The method of claim 134, wherein the virus that is reactivating is a herpesvirus.~~

~~136. The method of claim 135, wherein said herpesvirus is chosen from HSV-1, HSV-2 and Epstein-Barr virus.~~

~~137. The method of claim 134, wherein the virus that is reactivating is HIV.~~


~~138. The method of any of claims 116 to 137, wherein said subject is a human.~~

~~139.~~117. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which comprises reacting a compound of formula II



II

wherein A, B, R^w, R^x, R^y, and R^z have the meanings defined for the compound of formula I in claim 1, with a compound of formula III



III

wherein D has the meaning defined for the compound of formula I in claim 1, and wherein the group(s) R^3 on ring D are optionally protected with a protecting group,

in the presence of a reducing agent, followed by the removal of any protecting group that may be present.

~~140.~~118. The process of claim ~~139~~ 117, wherein said reducing agent is a borohydride.